The Impact of Opioids in Coronary Heart Disease

Evaluation of Past Medications in Patients With Coronary Heart Disease and Patients Hospitalized for a Non-cardiac Reason

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02740621

Acronym

MIOP/TRAPS

Enrollment

750

Registered

2016-04-15

Start date

2016-01-31

Completion date

2017-08-31

Last updated

2018-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Brief summary

In this study, the risk of opioid medications on coronary heart disease in adults is investigated. Patients with the necessity of a coronary angiography and control patients with a non-cardiac disease of the same hospital are inquired with a standardized questionnaire about demographic and clinical risk factors for heart attack. An impact of opioid medications on coronary heart disease is hypothesised (MIOP). In addition, all patients with coronary angiography should be consulted twice (after 3 and 6 months) to find out how many of these patients have developed a refractory angina pectoris (TRAPS).

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

* 40 years or older * written informed consent

Exclusion criteria

* currently cancer * cognitive limitations

Design outcomes

Primary

Measure	Time frame	Description
Number of patients with opioid treatment (WHO II/ WHO III) within the last 10 years before present hospitalization, Interview with standardized CRF	20 minutes	Standardized assessment of opioid medications taken before hospital admission to evaluate the impact of opioids in coronary heart disease. Exact doses, substances and intake habits are inquired.
Number of patients with refractory angina pectoris, Interview with standardized CRF	30 minutes	Standardized assessment of angina pectoris symptoms and treatments to evaluate a refractory angina pectoris. Changes of their medications are inquired twice.

Countries

Germany

Outcome results